Aristides Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Aristides Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,900	Closed	-$197K	–	329
2024 Q4	$197K	Buy	+14,900	New	+$255K	0.04%	247

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aristides Capital's SNDX Position: Q1 2025 in Review

Aristides Capital sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 14,900 shares — an estimated $197K sold.

Aristides Capital first reported a position in SNDX in Q4 2024 and held it in 1 quarter. The position peaked at $197K in Q4 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

Aristides Capital reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 14,900 Syndax Pharmaceuticals shares in Q1 2025, an estimated $197K.
Aristides Capital first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Aristides Capital's Syndax Pharmaceuticals position peaked at $197K in Q4 2024.
218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.